Owkin launches AI-powered program to unify biomedical data

FRANCE – Owkin has introduced ATLANTIS, an AI-driven patient data discovery program designed to analyze complex medical information, including imaging, genomics, and clinical records.

The insights from ATLANTIS will power Owkin’s AI co-pilot, Owkin K, to speed up drug discovery and diagnostics.

Addressing data fragmentation

A major challenge in medical research is that data is scattered across different institutions and departments, making it difficult to utilize effectively.

ATLANTIS aims to unify and map data across multiple therapeutic areas, ensuring that AI can drive medical breakthroughs.

The program focuses on 11 disease areas, including:

• Oncology: Non-small-cell lung cancer, head and neck squamous cell carcinoma, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and multiple myeloma.
• Immunology: Ulcerative colitis, Crohn’s disease, and systemic lupus erythematosus.
• Neurology: Alzheimer’s disease.

Global collaboration for AI-powered research

A consortium of 20 international healthcare institutions has partnered with ATLANTIS to enhance AI research and uncover new insights from multimodal data.

Among these institutions are Cooper University Health Care, The Royal Marsden NHS Foundation Trust, Washington University in St. Louis, Leipzig University, Sheba Medical Center, and Aster Insights.

Owkin’s SVP of Partnerships, Agathe Arlotti, emphasized the importance of collaboration between data scientists and healthcare institutions, stating:

“By combining AI expertise with leading healthcare partners, we are creating a patient data network that pushes the boundaries of biomedical research and fuels breakthroughs for patients.”

Advancing drug discovery with AI

ATLANTIS, which started in September 2024, is expected to conclude by May 2025. The data it generates could accelerate AI-driven drug development, much like Owkin’s recent success with OKN4395, an AI-designed cancer drug currently in Phase I trials.

Last month, Owkin also announced a partnership with Absci, another generative AI firm, to fast-track the discovery of new therapeutics.